Pfizer (NYSE:PFE) Stock Price Expected to Rise, UBS Group Analyst Says

Pfizer (NYSE:PFE) had its price target lifted by UBS Group from $24.00 to $25.00 in a research report sent to investors on Wednesday morning,Benzinga reports. UBS Group currently has a neutral rating on the biopharmaceutical company’s stock.

Other equities analysts also recently issued reports about the company. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective on the stock. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Stock Performance

Pfizer stock opened at $24.19 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a fifty day moving average price of $24.34 and a two-hundred day moving average price of $25.78. The company has a market cap of $137.19 billion, a PE ratio of 17.16, a P/E/G ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the previous year, the firm posted $0.82 earnings per share. Pfizer’s quarterly revenue was down 7.8% compared to the same quarter last year. Research analysts expect that Pfizer will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.11%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s payout ratio is 124.64%.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of PFE. Passumpsic Savings Bank increased its position in Pfizer by 8.4% during the third quarter. Passumpsic Savings Bank now owns 25,680 shares of the biopharmaceutical company’s stock worth $743,000 after acquiring an additional 1,998 shares during the period. Virtu Financial LLC bought a new position in shares of Pfizer during the 3rd quarter worth about $1,499,000. Westside Investment Management Inc. raised its position in shares of Pfizer by 7.7% during the third quarter. Westside Investment Management Inc. now owns 14,008 shares of the biopharmaceutical company’s stock valued at $404,000 after buying an additional 1,004 shares during the last quarter. Diamant Asset Management Inc. lifted its stake in shares of Pfizer by 8.4% in the third quarter. Diamant Asset Management Inc. now owns 8,515 shares of the biopharmaceutical company’s stock valued at $246,000 after buying an additional 660 shares during the period. Finally, Morse Asset Management Inc acquired a new stake in Pfizer during the third quarter worth about $2,649,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.